Last Updated February 29, 2024

 February 29, 2024

Researchers working in the areas of injury recovery and wound healing may be interested in the latest evidence on BPC-157 dosage.

Yet finding reliable information may be challenging because, like many research peptides, BPC-157 lacks standardized dosing and administration guidelines.

Guidance on this front is important since research has uncovered that BPC-157 may have important research applications like:

  • Improving injury recovery
  • Stimulating wound healing
  • Reducing gut inflammation

Below, we detail what researchers must know about experimenting with this peptide, along with presenting a BPC-157 dosage calculator, safety protocols, and potential side effects.

Buy BPC-157 from our top-rated vendor...

Disclaimer: contains information about products that are intended for laboratory and research use only, unless otherwise explicitly stated. This information, including any referenced scientific or clinical research, is made available for educational purposes only. Likewise, any published information relative to the dosing and administration of reference materials is made available strictly for reference and shall not be construed to encourage the self-administration or any human use of said reference materials. makes every effort to ensure that any information it shares complies with national and international standards for clinical trial information and is committed to the timely disclosure of the design and results of all interventional clinical studies for innovative treatments publicly available or that may be made available. However, research is not considered conclusive. makes no claims that any products referenced can cure, treat or prevent any conditions, including any conditions referenced on its website or in print materials.

BPC-157 Dosage Chart | Quick Breakdown

Timeline Week 1-2 Week 3-4
Four-Week Protocol for Healing and Repair Research 500mcg-750mcg daily (2-3 injections) 250mcg-500mcg daily (1-2 injections)

What is BPC-157?

BPC-157 (Body Protection Compound-157) is a synthetic peptide comprising 15 amino acids, thus making it a pentadecapeptide.

It was first developed in 1991 as a derivative of Body Protection Compound, a peptide naturally found in human gastric juices [1, 2].

BPC-157 was initially investigated for preventing and managing stomach ulcers, and further research delved into its potential for improving wound and injury healing in test subjects [3].

Researchers posit that there are multiple mechanisms through which BPC-157 promotes healing effects when administered to test subjects:

  • BPC-157 is notably thought to work by stimulating the formation of blood vessels, in a process known as angiogenesis. It may achieve this by upregulating vascular endothelial growth factor (VEGF), an endogenous protein responsible for stimulating the growth of new blood vessels [4].
  • BPC-157 may also upregulate the expression of early growth response gene-1 (EGR-1), which is a growth factor with potential benefits for the nervous system, having been suggested to aid in early extracellular matrix (collagen) formation [5].
  • Researchers also suggest that BPC-157 increases blood flow in the body by increasing the production and release of nitric oxide (NO). In fact, animal studies into the effects of BPC-157 on nitric oxide have shown that it can accelerate recovery rates in a wide variety of injuries [6].

As of writing, no clinical studies are available on the effects and safety of BPC-157. Thus, it remains classed as a research chemical that is available for laboratory experimentation.

BPC-157 Dosage Calculator

Research Application and Potential Benefits of BPC-157

BPC-157 has been studied for its potential benefits in various tissue and healing models.

Researchers have demonstrated its potential to reduce inflammation, speed up wound healing, and hasten recovery from various injuries.

BPC-157 and Musculoskeletal Injuries

Below we detail some of the more notable animal experiments that report on the healing potential of BPC-157.

  • Animal studies indicate BPC-157 may aid in healing injuries—particularly of tendons, muscles, and bones—by promoting angiogenesis and fibroblast growth [7].
  • In vitro research on cut tendons suggests that BPC-157 may enhance the migration of tendon fibroblasts to sites of injury [8].
  • Research shows improved healing in animal models of crushed muscles treated with BPC-157 [4].
  • Studies on the effects of BPC-157 on early Achilles tendon-to-bone recovery in rats demonstrate reduced inflammation and enhanced angiogenesis, collagen organization, and vascularity. The peptide was shown to counteract the negative effects of methylprednisolone [9, 10].
  • Studies in rabbits with partially healed bone defects show significant improvement with BPC-157 injections, yielding effects comparable to bone marrow or cortical graft procedures [11].
  • Additional animal injury models highlight the anti-inflammatory and pain reduction properties of BPC-157 [12, 13].

BPC-157 and Neuroprotection

Preliminary experiments also suggest that BPC-157 may have protective effects on nervous tissue, particularly in laboratory models of toxicity and traumatic brain injury.

  • A 2014 study showed that BPC-157 reduced methamphetamine-induced neurotoxicity in rats, preserving more normal neurons compared to the control group [14].
  • In a mouse model of traumatic brain injury (TBI), BPC-157 administration significantly lowered damage and mortality rates. Further, prophylactic use prior to TBI decreased the risk of unconsciousness or death [15].

BPC-157 and Wound Healing

BPC-157 has shown potential for the recovery of various injuries and wounds affecting the digestive system and the skin. Here are some notable findings to date:

  • A rat study demonstrated that BPC-157 at high doses significantly boosted ileoileal anastomosis healing with minimal adhesions and increased granulation tissue and collagen [16].
  • In rats with short bowel syndrome, BPC-157 caused immediate weight gain and improved intestinal features following oral and intraperitoneal administration [17].
  • Reviews indicate the protective effects of BPC-157 on stomach cells following application of non-steroidal anti-inflammatory drugs (NSAIDs), as well as its role in maintaining gastric mucosa integrity [3, 18, 19].
  • Studies also suggest that BPC-157 speeds up skin wound healing, as seen in rats with alkali burns treated topically with the peptide [20].

BPC-157 Dosage Calculator

There is currently a lack of clinical research that offers specific dosing guidelines for BPC-157.

As a result, the existing recommendations on how to dose this compound largely stem from animal studies and anecdotal reports.

Based on current information, we’ll outline how to estimate BPC-157 dosage in various experimental settings.

Dosing BPC-157 For Healing

Animal research exploring the healing capabilities of BPC-157 has mostly involved rodents, with doses reaching up to 10mcg/kg daily [21]. To calculate a comparable dosage to apply in clinical settings, researchers may refer to the dose conversion guidelines established by Nair et al. (2016).

Based on this publication, the conversion rate from rat to human doses is about 1:6.2. Therefore, a rat dosage of 10mcg/kg translates to roughly 1.61mcg/kg for human subjects [22]. This equates to approximately 0.73mcg/lb, or about 146mcg for an individual weighing 200lb.

Additionally, animal studies have administered BPC-157 for periods exceeding 14 days without observing any significant safety concerns or adverse effects [16]. Nevertheless, it is important to recognize that these findings may not directly translate to clinical settings.

Dosing BPC-157 Oral Capsules

Preclinical experiments reveal that BPC-157 may also be administered orally, such as in the form of BPC-157 capsules, especially during research related to gut healing. Yet, it is unknown if this formulation would exert primarily local effects on the digestive system, or if it would work systemically.

The BPC-157 oral doses used in preclinical studies is similar to those given in studies with injections at 10mcg/kg [21].

Anecdotal reports also suggest that research with oral formulations of BPC-157 may be conducted with similar dosages to the ones estimated via the aforementioned calculations. More specifically, the most widely speculated daily dosage for BPC-157 oral capsules is around 250mcg, typically administered 1-3 times daily.

Yet, more research is needed to evaluate and confirm the safety and effectiveness of such dosing regimes.

Dosing BPC-157 Nasal Spray

BPC-157 as a nasal spray may be a valuable tool for researchers interested in investigating the potential of BPC-157 for neuroprotection. Yet, similar to other BPC-157 formulations, there is no data on the proper dosing of BPC-157 nasal spray in research settings.

Therefore, researchers may consider using doses similar to those administered as BPC-157 injections or BPC-157 oral capsules.

BPC-157 + TB-500 Blend Dosage Calculator

BPC-157 is also commonly sold as a blend with TB-500.

TB-500 is a synthetic version of the endogenous protein called thymosin beta-4, which is found in most human and animal cells. Thymosin beta-4 promotes a variety of essential biological functions such as [22]:

  • Reducing inflammation
  • Angiogenesis
  • Immune support
  • Faster wound healing

Combining this compound with BPC-157 is thought to lead to synergistic healing effects, which has led to the development of peptide blends for use in such experiments. BPC-157 + TB-500 blends typically contain the two peptides in a ratio ranging from 1:1 to 1:5 in favor of TB-500.

This is because TB-500 research suggests that it can be applied in daily doses starting from 0.5mcg/kg of body weight up to considerably higher doses for 10-14 days [23, 24].

Based on this, anecdotal sources report a dose of 10-20mcg/kg, which would be equal to 1-2mg for a 200lb test subject.

Considering this information, dosing a 1:1 blend of BPC-157 + TB-500 at 1mcg/kg daily (0.5mcg/kg each) may be a decent starting point for most researchers.

How to Mix and Reconstitute BPC-157

BPC-157 for injection is typically shipped as a lyophilized powder that needs to be reconstituted using a sterile solvent such as bacteriostatic water.

This solvent contains 0.9% benzyl alcohol—a preservative that suppresses microbial growth and ensures a 4-week shelf-life of the peptide when refrigerated at 35-46°F (2-8°C).

Here is a short guide on how researchers can successfully reconstitute BPC-157.

Step 1: Collection of Required Materials

For the preparation process, researchers will need to gather several items, including:

  • Bacteriostatic water
  • Insulin syringes
  • Alcohol pads
  • Sterile storage vial
  • 3cc syringe with needle

Step 2: Calculating Correct Volumes

Researchers may refer to this calculator tool to ascertain the precise volume of bacteriostatic water needed. This calculation is essential to achieve the desired concentration when mixed with BPC-157 powder.

Step 3: Combining Bacteriostatic Water and BPC-157 Powder

The process involves using a 3cc syringe and needle. Firstly, draw an amount of air equivalent to the required volume of bacteriostatic water. Then, insert the needle into the bacteriostatic water vial and release the air to prevent a vacuum effect. Next, withdraw the necessary volume of diluent. While mixing, angle the needle into the BPC-157 vial and carefully depress the plunger, guiding the water along the inner surface of the vial. After the syringe is emptied, remove it from the vial.

Step 4: Dissolution of the Peptide

It's crucial to avoid agitating the vial, whether by shaking or tapping. Instead, let the vial rest for 10 to 20 minutes or use sonication if available. This period allows the BPC-157 peptide to dissolve completely. In case any particles remain undissolved, gently roll the vial to aid in completing the reconstitution process.

This methodical approach ensures a precise and effective preparation of the peptide solution for research purposes, maintaining the integrity and effectiveness of the BPC-157.

How Much Bacteriostatic Water to Mix With 5mg of BPC-157?

Researchers aiming to reconstitute 5mg vials of BPC-157 may wonder how much bacteriostatic water to use during the process.

When reconstituting 5mg of BPC-157, scientists must note that the volume of solvent used can vary depending on the desired concentration. A common approach is to use a 1mL syringe for precision.

Thus, for a concentration of 1mg/mL, which is often used for ease of calculation, researchers can mix 5mg of BPC-157 with 5mL of bacteriostatic water. This allows for easy dosing where 0.25mL of the solution contains 250mcg of BPC-157.

Further, researchers should always use aseptic techniques to ensure the purity and sterility of the mixture and refer to the label of the peptide for accurate information on reconstitution, handling, and storage.

How Much Bacteriostatic Water to Mix With 10mg of BPC-157?

For reconstituting a 10mg vial of BPC-157, researchers can follow a similar approach. For example, scientists can use 10mL of bacteriostatic water and aim for a concentration of 1mg/mL, thus making calculations considerably easier.

Consequently, 0.25mL of the solution will again contain 250mcg of BPC-157.

This method ensures a precise concentration, facilitating accurate dosing for research purposes. The reconstituted peptide should be stored per recommended guidelines to maintain its stability and efficacy.

BPC-157 Dosage Calculator

Where to Buy BPC-157 Online? | 2024 Edition

Researchers interested in studying the potential benefits of BPC-157 will want to ensure that they source their reference materials from a legitimate vendor.

To assist researchers, our team has tested the top online peptide vendors and ranked them according to quality, price, and speed of delivery.

Ultimately, our experts identified two reliable vendors who we endorse for their product quality and service.

Limitless Life

Limitless Life is a Florida-based vendor of BPC-157 and a range of other premium research peptides.

We endorse this retailer for the following reasons:

  • High-Purity BPC-157: Limitless Life’s BPC-157 products undergo rigorous third-party analysis to ensure their potency and purity.
  • Product Seleciton: The vendor boasts an extensive catalog with a variety of BPC-157 options, including powder for injection, nasal spray, capsules, and a BPC-157/TB-500 blend.
  • Convenient Payments: The vendor offers a variety of convenient payment options, including major credit cards, Zelle, and even cryptocurrencies.
  • Service, Support, and Care: Limitless Life is known for their dedication to satisfaction. Their team is available during business hours by email and phone to address any questions or concerns.

But that’s not all! Use this coupon code to get a 10% discount from Limitless Life:


Buy BPC-157 from our top-rated vendor...

Xcel Peptides

We also recommend Xcel Peptides for the purchase of BPC-157 and other high-quality reference materials.

Despite being a newer business on the scene, Xcel Peptides delivers on these commitments:

  • Research-Grade BPC-157: Xcel Peptides sells strictly research-grade BPC-157 that is synthesized in registerd American facilities and third-party tested by a reputable laboratory for identity and purity.
  • Rapid Shipping: Domestic orders will usually arrive in 2-3 business days and attract a low shipping fee. Orders of $200+ get free shipping.
  • Outstanding Support: The vendor’s professional support team is highly knowledgeable about peptides and is sure to address all concerns as quickly as possible.

Don’t wait…sign up for the Xcel Peptides email newsletter to get a 10% discount when buying from this vendor!

Buy research peptides from Xcel Peptides today...

Is BPC-157 Safe?

The safety profile of BPC-157 is not well-established due to a lack of clinical data on the compound.

It has not been evaluated by bodies like the United States Food and Drug Administration (FDA) or comparable international agencies, leading to a significant gap in understanding its safety for human use. Therefore, any claims about the safety of BPC-157 should be treated with caution.

On the other hand, laboratory studies in animals indicate that BPC-157 is well-tolerated with minimal toxicity, even at elevated doses [25]. However, results from animal experiments cannot be extrapolated to clinical settings.

Without clinical data, it is challenging to ascertain the potential short-term or long-term adverse effects of BPC-157.

Particular attention should be paid to possible side effects linked to the method of administration, like subcutaneous injections, which might cause local reactions such as redness, swelling, or irritation.

Further, conducting research using BPC-157 nasal spray may lead to eye, nose, or throat irritation, sneezing, coughing, and other transitory complaints. These reactions are usually mild, short-lived, and resolve without medical intervention. Individual responses to BPC-157 can differ, with some subjects experiencing unique or additional side effects.

Although preclinical research indicates a favorable safety profile for BPC-157, even at high doses, the lack of comprehensive clinical data necessitates caution in research applications involving this peptide.

Is BPC-157 Legal?

BPC-157 as a research chemical is available in the United States for use by qualified researchers. It is important to note that this compound is not authorized for human use.

Researchers must be aware that BPC-157 cannot legally be marketed or sold as a dietary supplement. It is not available over-the-counter.

Avoid BPC-157 that is inaccurately labeled as a “supplement” or falsely claimed as an ingredient in supplements, which is against the law.

When distributed as a reference material, BPC-157 should be clearly and precisely labeled. Such labeling is crucial to distinguish it from consumer products and prevent any confusion or improper use.

BPC-157 Dosing | Verdict

BPC-157 is a peptide that has shown promise in various areas of medical research, such as tissue regeneration, wound healing, neuroprotection, and enhancing overall recovery processes.

However, the bulk of research is preclinical, with a significant lack of high-quality clinical trials. While animal studies have suggested numerous potential benefits of BPC-157, there is still a lack of clarity regarding its effects, side effects, and appropriate dosing in clinical settings.

Currently, BPC-157 is not authorized for human use as it lacks approval for any indication. The correct dosage for use outside of laboratory environments is still undetermined.

We advise researchers who are interested in studying BPC-157 to visit our #1 recommended vendor of research chemicals


  1. Sikirić, P., Petek, M., Rucman, R., Seiwerth, S., Grabarević, Z., Rotkvić, I., Turković, B., Jagić, V., Mildner, B., & Duvnjak, M. (1993). A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. Journal of physiology, Paris, 87(5), 313–327.
  2. Jelovac, N., Sikirić, P., Rucman, R., Petek, M., Perović, D., Konjevoda, P., Marović, A., Seiwerth, S., Grabarević, Z., Sumajstorcić, J., Dodig, G., & Perić, J. (1998). A novel pentadecapeptide, BPC 157, blocks the stereotypy produced acutely by amphetamine and the development of haloperidol-induced supersensitivity to amphetamine. Biological psychiatry, 43(7), 511–519.
  3. Sikiric, P., Hahm, K. B., Blagaic, A. B., Tvrdeic, A., Pavlov, K. H., Petrovic, A., Kokot, A., Gojkovic, S., Krezic, I., Drmic, D., Rucman, R., & Seiwerth, S. (2020). Stable Gastric Pentadecapeptide BPC 157, Robert's Stomach Cytoprotection/Adaptive Cytoprotection/Organoprotection, and Selye's Stress Coping Response: Progress, Achievements, and the Future. Gut and liver, 14(2), 153–167.
  4. Brcic, L., Brcic, I., Staresinic, M., Novinscak, T., Sikiric, P., & Seiwerth, S. (2009). Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 60 Suppl 7, 191–196.
  5. Tkalcević, V. I., Cuzić, S., Brajsa, K., Mildner, B., Bokulić, A., Situm, K., Perović, D., Glojnarić, I., & Parnham, M. J. (2007). Enhancement by PL 14736 of granulation and collagen organization in healing wounds and the potential role of egr-1 expression. European journal of pharmacology, 570(1-3), 212–221.
  6. Grabarevic, Z., Tisljar, M., Artukovic, B., Bratulic, M., Dzaja, P., Seiwerth, S., Sikiric, P., Peric, J., Geres, D., & Kos, J. (1997). The influence of BPC 157 on nitric oxide agonist and antagonist induced lesions in broiler chicks. Journal of physiology, Paris, 91(3-5), 139–149.
  7. Chang, C. H., Tsai, W. C., Hsu, Y. H., & Pang, J. H. (2014). Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules (Basel, Switzerland), 19(11), 19066–19077.
  8. Chang, C. H., Tsai, W. C., Lin, M. S., Hsu, Y. H., & Pang, J. H. (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of applied physiology (Bethesda, Md. : 1985), 110(3), 774–780.
  9. Krivic, A., Anic, T., Seiwerth, S., Huljev, D., & Sikiric, P. (2006). Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: Promoted tendon-to-bone healing and opposed corticosteroid aggravation. Journal of orthopaedic research : official publication of the Orthopaedic Research Society, 24(5), 982–989.
  10. Krivic, A., Majerovic, M., Jelic, I., Seiwerth, S., & Sikiric, P. (2008). Modulation of early functional recovery of Achilles tendon to bone unit after transection by BPC 157 and methylprednisolone. Inflammation research : official journal of the European Histamine Research Society … [et al.], 57(5), 205–210.
  11. Sebecić, B., Nikolić, V., Sikirić, P., Seiwerth, S., Sosa, T., Patrlj, L., Grabarević, Z., Rucman, R., Petek, M., Konjevoda, P., Jadrijević, S., Perović, D., & Slaj, M. (1999). Osteogenic effect of a gastric pentadecapeptide, BPC-157, on the healing of segmental bone defect in rabbits: a comparison with bone marrow and autologous cortical bone implantation. Bone, 24(3), 195–202.
  12. Sikirić, P., Gyires, K., Seiwerth, S., GrabarevlĆ, Z., Ručman, R., Petek, M., … & Bura, M. (1993). The effect of pentadecapeptide BPC 157 on inflammatory, non-inflammatory, direct and indirect pain and capsaicin neurotoxicity. Inflammopharmacology, 2, 121-127.
  13. Keremi, B., Lohinai, Z., Komora, P., Duhaj, S., Borsi, K., Jobbagy-Ovari, G., Kallo, K., Szekely, A. D., Fazekas, A., Dobo-Nagy, C., Sikiric, P., & Varga, G. (2009). Antiinflammatory effect of BPC 157 on experimental periodontitis in rats. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 60 Suppl 7, 115–122.
  14. Suran, J., Kolenc, D., Prevendar Crnic, A., Radic, B., Drmic, I., Seiwerth, S., & Sikiric, P. (2014). The effect of pentadecapeptide BPC 157 in metamphetamine‐induced dopaminergic neurotoxicity (1143.11). The FASEB Journal, 28, 1143-11.
  15. Tudor, M., Jandric, I., Marovic, A., Gjurasin, M., Perovic, D., Radic, B., Blagaic, A. B., Kolenc, D., Brcic, L., Zarkovic, K., Seiwerth, S., & Sikiric, P. (2010). Traumatic brain injury in mice and pentadecapeptide BPC 157 effect. Regulatory peptides, 160(1-3), 26–32.
  16. Vuksic, T., Zoricic, I., Brcic, L., Sever, M., Klicek, R., Radic, B., Cesarec, V., Berkopic, L., Keller, N., Blagaic, A. B., Kokic, N., Jelic, I., Geber, J., Anic, T., Seiwerth, S., & Sikiric, P. (2007). Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL-10, PLD-116, PL14736, Pliva, Croatia) heals ileoileal anastomosis in the rat. Surgery today, 37(9), 768–777.
  17. Sever, M., Klicek, R., Radic, B., Brcic, L., Zoricic, I., Drmic, D., Ivica, M., Barisic, I., Ilic, S., Berkopic, L., Blagaic, A. B., Coric, M., Kolenc, D., Vrcic, H., Anic, T., Seiwerth, S., & Sikiric, P. (2009). Gastric pentadecapeptide BPC 157 and short bowel syndrome in rats. Digestive diseases and sciences, 54(10), 2070–2083.
  18. Sikiric, P., Seiwerth, S., Rucman, R., Drmic, D., Stupnisek, M., Kokot, A., Sever, M., Zoricic, I., Zoricic, Z., Batelja, L., Ziger, T., Luetic, K., Vlainic, J., Rasic, Z., & Bencic, M. L. (2017). Stress in Gastrointestinal Tract and Stable Gastric Pentadecapeptide BPC 157. Finally, do we have a Solution?. Current pharmaceutical design, 23(27), 4012–4028.
  19. Sikiric, P., Drmic, D., Sever, M., Klicek, R., Blagaic, A. B., Tvrdeic, A., Kralj, T., Kovac, K. K., Vukojevic, J., Siroglavic, M., Gojkovic, S., Krezic, I., Pavlov, K. H., Rasic, D., Mirkovic, I., Kokot, A., Skrtic, A., & Seiwerth, S. (2020). Fistulas Healing. Stable Gastric Pentadecapeptide BPC 157 Therapy. Current pharmaceutical design, 26(25), 2991–3000.
  20. Huang, T., Zhang, K., Sun, L., Xue, X., Zhang, C., Shu, Z., Mu, N., Gu, J., Zhang, W., Wang, Y., Zhang, Y., & Zhang, W. (2015). Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro. Drug design, development and therapy, 9, 2485–2499.
  21. Klicek, R., Kolenc, D., Suran, J., Drmic, D., Brcic, L., Aralica, G., Sever, M., Holjevac, J., Radic, B., Turudic, T., Kokot, A., Patrlj, L., Rucman, R., Seiwerth, S., & Sikiric, P. (2013). Stable gastric pentadecapeptide BPC 157 heals cysteamine-colitis and colon-colon-anastomosis and counteracts cuprizone brain injuries and motor disability. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 64(5), 597–612.
  22. Nair, A. B., & Jacob, S. (2016). A simple practice guide for dose conversion between animals and human. Journal of basic and clinical pharmacy, 7(2), 27–31.
  23. Ruff, D., Crockford, D., Girardi, G., & Zhang, Y. (2010). A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Annals of the New York Academy of Sciences, 1194, 223–229.
  24. Wang, X., Liu, L., Qi, L., Lei, C., Li, P., Wang, Y., Liu, C., Bai, H., Han, C., Sun, Y., & Liu, J. (2021). A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers. Journal of cellular and molecular medicine, 25(17), 8222–8228.
  25. Seiwerth, S., Milavic, M., Vukojevic, J., Gojkovic, S., Krezic, I., Vuletic, L. B., Pavlov, K. H., Petrovic, A., Sikiric, S., Vranes, H., Prtoric, A., Zizek, H., Durasin, T., Dobric, I., Staresinic, M., Strbe, S., Knezevic, M., Sola, M., Kokot, A., Sever, M., … Sikiric, P. (2021). Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. Frontiers in pharmacology, 12, 627533.

Scientifically Fact Checked by:

David Warmflash, M.D.

Table of Contents
    Add a header to begin generating the table of contents